Taysha Gene TherapiesÂ Inc (TSHA) Peer Comparison

$5.06

$0.05 (1.00%)

As on 15-Sep-2026 16:00EDT

Market cap

$1,636 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

--

P/B Ratio

4.3

Div. Yield

0 %

Edit

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	1,636	17,335	16,399	13,906	12,167
Revenue ($ Mln)	5	1,054	2,782	2,436	1,664
Net Profit ($ Mln)	-149.63	755.85	491.50	860.62	413.60
Net Margin (%)	-2,728.04	71.69	17.67	35.33	24.86
RoE (%)	-47.19	--	110.09	42.98	430.03
Price to Earnings	--	20.24	34.46	17.65	31.44
Price-To-Book	4.34	10.29	37.52	7.54	84.60

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	5.49	1,054.37	2,782.29	2,435.92	1,663.74
Cost of Revenue	0.88	103.47	1,982.07	85.67	363.07
Gross Profit	9.77	588.53	760.62	2,236.43	1,091.18
Operating Expenses	157.76	841.45	216.81	1,378.74	356.18
Operating Profit (EBIT)	-153.16	109.45	583.40	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-149.63	101.11	598.92	1,035.47	583.34
Provision for Tax	0.00	-654.74	107.42	174.84	169.74
Profit after Tax (Net Income)	-149.63	755.85	491.50	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	387.27	1,435.90	433.86	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	57.19	384.48	187.89	288.55	2,089.43
Current Liabilities	25.98	464.70	1,435.43	361.93	344.44
Total Liabilities	343.32	1,302.02	1,975.47	2,844.42	2,525.32

Assets ($ Mln)

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	9.00	895.24	1,006.90	1,243.41	1,644.38
Current Assets	461.43	1,389.84	1,050.29	1,250.82	933.02
Total Assets	343.32	1,302.02	1,975.47	2,844.42	2,525.32
Total Debt*	55.55	449.89	120.10	165.93	2,146.65
Net Current Assets	435.46	925.52	-385.14	888.90	588.59

Cashflow ($ Mln)

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-93.09	51.77	713.22	884.27	651.56
Cash Flow from Investing Activities	-0.60	-8.15	-31.14	350.44	-545.81
Cash from Financing Activities	274.59	34.89	-860.39	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-54.52	-30.01	53.56	32.82	15.61
ROE (%)	-47.19	163.18	110.09	42.98	430.03
ROA (%)	-35.00	31.68	15.64	29.32	16.19
EBIT Margin (%)	-2,735.68	5.73	21.13	31.04	36.28
Net Margin (%)	-2,728.04	71.69	17.67	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-32.27	114.85	24.67	9.23	41.15
EBIT Growth (%)	-61.98	136.39	18.70	-3.99	-14.99
Net Profit Growth (%)	-61.38	378.76	17.50	42.89	-25.78
EPS Growth (%)	-18.12	353.27	26.84	50.42	-23.48
Book Value Growth (%)	25.72	816.12	164.02	-0.70	-55.81

Valuation Ratios

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-16.13	-59.76	36.06	15.79	24.99
Price / Book Value	7.12	-80.42	35.44	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-13.52	-121.54	28.08	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.13	0.27	0.00	0.00	13.50
Short term debt to equity ratio	0.00	0.05	0.00	0.00	1.46
Current Ratio	17.76	2.99	0.73	3.46	2.71
Quick Ratio	17.76	2.32	0.73	3.38	2.31
Interest Coverage	-3,561.69	1.62	--	--	29.73

Operating Efficiency Ratios

	Taysha Gene TherapiesÂ Inc (TSHA)	Ascendis Pharma A/S - ADR	Medpace Holdings (MEDP)	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	0.00	21.25	15.88	13.74	27.40
Asset Turnover	0.01	0.44	0.89	0.83	0.65
Receivable days	--	85.52	50.42	43.48	98.04
Inventory Days	--	1,056.70	--	96.17	190.34
Payable days	1,573.76	331.01	6.26	147.97	18.62
Cash Conversion Cycle	--	811.21	--	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly